Legend Biotech CorporationLEGNNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank42
5Y CAGR-1.5%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-1.5%/yr
Long-term compound
Percentile
P42
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 8.29% |
| Q2 2025 | 11.34% |
| Q1 2025 | -12.86% |
| Q4 2024 | 4.47% |
| Q3 2024 | 21.64% |
| Q2 2024 | 16.50% |
| Q1 2024 | -9.99% |
| Q4 2023 | 41.68% |
| Q3 2023 | -10.47% |
| Q2 2023 | 22.47% |
| Q1 2023 | -15.02% |
| Q4 2022 | 12.26% |
| Q3 2022 | -7.46% |
| Q2 2022 | 33.96% |
| Q1 2022 | -51.45% |
| Q4 2021 | 123.22% |
| Q3 2021 | 20.39% |
| Q2 2021 | 17.47% |
| Q1 2021 | -33.56% |
| Q4 2020 | 117.64% |
| Q3 2020 | 8.96% |
| Q2 2020 | 41.00% |
| Q1 2020 | -35.32% |
| Q4 2019 | 139.03% |
| Q3 2019 | -2.79% |
| Q2 2019 | 71.90% |
| Q1 2019 | 0.00% |